Antimicrobial Spectrum of Amikacin
Amikacin is a broad-spectrum aminoglycoside antibiotic that is bactericidal against most aerobic Gram-negative bacteria (including Pseudomonas, E. coli, Proteus, Klebsiella, Enterobacter, Serratia, and Acinetobacter species) and has activity against Staphylococcus species, with the critical advantage of resisting degradation by many aminoglycoside-inactivating enzymes that affect gentamicin and tobramycin 1.
Primary Spectrum Coverage
Gram-Negative Bacteria (Primary Targets)
Amikacin demonstrates excellent activity against:
- Pseudomonas species (including P. aeruginosa)
- Escherichia coli
- Proteus species (both indole-positive and indole-negative)
- Klebsiella species
- Enterobacter species
- Serratia species
- Acinetobacter species
- Providencia species
- Citrobacter freundii (in vitro activity documented) 1
Gram-Positive Bacteria (Limited Activity)
- Staphylococcus species (including S. aureus) 1
- Aminoglycosides generally have low activity against other Gram-positive organisms 1
Key Clinical Advantages
Resistance Profile
Amikacin is the aminoglycoside of choice when gentamicin or tobramycin resistance is suspected 2, 3. The drug resists degradation by certain aminoglycoside-modifying enzymes (AMEs) that inactivate gentamicin, tobramycin, and kanamycin 1, 3. This makes it particularly valuable in settings with high rates of extended-spectrum β-lactamase (ESBL)-producing organisms 2.
Synergistic Activity
When combined with β-lactam antibiotics (particularly acylureidopenicillins and third-generation cephalosporins), amikacin demonstrates in vitro synergistic activity against many clinically significant Gram-negative organisms 1, 3. Importantly, amikacin is the aminoglycoside least inactivated by semisynthetic penicillins 3.
Important Limitations and Caveats
Organisms with Poor/No Activity
- Salmonella and Shigella species: Aminoglycosides are known to be ineffective in patients, and susceptibility results should not be reported 1
- Anaerobic bacteria: No meaningful activity
- Most Gram-positive organisms (except Staphylococcus): Low order of activity 1
Clinical Context from Guidelines
The 2024 WHO Essential Medicines guidelines specifically recommend amikacin over gentamicin for severe pyelonephritis and prostatitis because "amikacin is considered to have a better resistance profile, is still effective against isolates producing extended-spectrum β-lactamases and is considered an appropriate carbapenem-sparing option in settings where extended-spectrum β-lactamases-producing isolates are very prevalent" 2.
For necrotizing fasciitis with mixed infections, amikacin (or other aminoglycosides) is recommended as part of combination therapy for coverage against resistant Gram-negative rods 4.
Practical Considerations
On a weight basis, gentamicin and tobramycin are more active in vitro than amikacin; however, amikacin achieves higher serum levels, which compensates for this difference 5. This pharmacokinetic advantage, combined with its superior resistance profile, makes amikacin the preferred aminoglycoside when dealing with potentially resistant organisms or in settings with high aminoglycoside resistance rates 3, 6.
The drug's spectrum makes it particularly valuable for empiric therapy in febrile, leukopenic immunocompromised hosts when combined with β-lactam antibiotics, as it exhibits enhanced activity against organisms most frequently encountered in this population 3.